---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-010515"
form_type: "8-K"
ticker: "SABS"
cik: "0001833214"
company_name: "SAB Biotherapeutics, Inc."
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:56:41.751327+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "low"
source: SEC EDGAR
---

# SAB Biotherapeutics posts updated corporate presentation; no financial or operational details disclosed

## Summary
- Filed under Item 7.01 Regulation FD; presentation posted on company website.
- No specific financial metrics, pipeline updates, or guidance changes provided in the filing.
- Presentation titled 'Modifying Disease, Delaying Progression, Transforming Treatment' suggests therapeutic focus.

## SEC filing metadata
- accession: 0001193125-26-010515
- form_type: 8-K
- ticker: SABS
- cik: 0001833214
- company_name: SAB Biotherapeutics, Inc.
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1833214/000119312526010515/0001193125-26-010515-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1833214/000119312526010515/sabs-20260112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-010515
- JSON: https://secwatch.observer/filing/0001193125-26-010515.json
- Plain text: https://secwatch.observer/filing/0001193125-26-010515.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.